Otros idiomas Prescient Therapeutics Limited

Acciones

PTX

AU000000PTX3

Mercado cerrado - Australian S.E. Otros sitios de cotización 07:59:24 17/05/2024			Varia. Cinco días.	Varia. 1 de enero.
0,043 ^AUD	-2,27 %		0,00 %	-30,65 %

25/03	Transcript : Prescient Therapeutics Limited - Special Call
23/02	Prescient Therapeutics Limited informa de los resultados del semestre finalizado el 31 de diciembre de 2023	CI

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

Prescient Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2023	23/02
Prescient Therapeutics Receives AU$2.4 Million R&D Tax Rebate; Shares Down 4%	28/11
Prescient Therapeutics Limited Reports Earnings Results for the Full Year Ended June 30, 2023	25/08/23
Prescient Therapeutics showcases cell therapy data at prestigious ISCT conference	16/06/23
Prescient Therapeutics Limited Appoints Ellen Feigal to the Board as Non- Executive Director	15/05/23
Prescient Therapeutics Limited Provides an Update on the PTX-100 Phase 1b Expansion Cohort in Relapsed and Refractory T Cell Lymphomas	15/03/23
Prescient Therapeutics thrilled with additional Orphan Drug Designation status for PTX-100	09/03/23
Prescient Therapeutics Secures US FDA Orphan Drug Designation for Lymphoma Medication; Shares Surge 29%	09/03/23
Prescient Therapeutics Announces FDA Grants Broader Orphan Drug Status to PTX-100 for TCL Indications	08/03/23
Prescient Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2022	24/02/23
Prescient Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2022	24/02/23
Prescient Therapeutics Sees Positive Results in PTX-100 Study	26/10/22
Prescient Therapeutics Limited Announces PTX-100 Trial Update	25/10/22
Prescient Therapeutics Unveils Cancer Drug CellPryme-A; Shares Rise 3%	23/09/22
Prescient Therapeutics Unveils CellPryme-A to Boost Car-T Performance	23/09/22
Prescient Therapeutics, MD Anderson Cancer Center to Develop Blood Cancer Binder for OmniCAR; Shares Rise 3%	07/09/22
Prescient Therapeutics Announces a Strategic Collaboration with the Larger Cancer Centre in the US1, the University of Texas MD Anderson Cancer Center	07/09/22
Prescient Therapeutics Launches $6 Million Share Purchase Plan	24/08/22
Prescient Therapeutics Limited Signs Agreement with Thermo Fisher Scientific to Accelerate OmniCAR Platform Development	18/08/22
Prescient Therapeutics Enters Manufacturing Deal for CAR-T Therapy OmniCAR for Clinical Trials Ahead	16/08/22

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Prescient Therapeutics Limited

Acciones

PTX

AU000000PTX3

Otros idiomas

Filtros